For now, MRI scans have played a very important role in ensuring that the treatment is precisely targeted to the correct area. By stimulating the correct area, the treatment is also more effective. Treatments given with competitors’ devices do not hit the right spot as precisely, nor does the treatment location stay in the same spot as accurately between treatment sessions as with Nexstim’s devices. For example, with Brainsway’s helmet, treatment is applied to a much larger area, hoping that it hits the right spot. This also leads to more severe side effects from the treatment.
7 Likes
I agree with Kyhnykeisari. It’s unlikely that the head MRI will be removed, as the entire Nexstim treatment is based on it. When the treatment can be calibrated to the patient’s own MRI image, the accuracy reaches a different level than otherwise.
Are these approvals also coming to the EU? I hope so. 
Edit:
Or did the doctor in the video at least claim that an MRI would not be needed in the future? Have they verified that the accuracy is sufficient without an MRI, or was it just speculation from the doctor in the video? I don’t recall any mention that a head MRI would no longer be needed. It would be great if they have found a way to maintain good accuracy without an MRI, but I’m a bit skeptical about this until Karvinen mentions it or an official announcement is made 
.
1 Like
Perhaps the most important takeaway from that video regarding the use of MRI scans was not whether they will be eliminated or not, but that when competing for equipment tenders, Nexstim’s device will (possibly) be an even more attractive option.
For hospitals and clinics, the device would enable the provision of treatment in the future without an MRI scan, at the same basic level (presumably) as competing solutions. However, with an MRI scan, treatment can be individualized, which brings added value compared to other equipment suppliers.
This gives the treatment provider flexibility in costs, and the device is seen as a more attractive and differentiating factor in the market: they can offer cost-effective basic treatment to the client or, if necessary, more precise, imaging-based treatment with the same device.
5 Likes
Here are Antti’s comments on Nexstim’s marketing authorizations. 
Nexstim announced on Monday that it had received marketing authorization from the US Food and Drug Administration (FDA) for its NBS 6 system as an add-on treatment for obsessive-compulsive disorder (OCD) and for the treatment of adolescent depression. These approvals are a continuation of the company’s strategy to expand the indications for its latest device and broaden customers’ opportunities to utilize the NBS 6 platform for treating different patient groups. The positive news supports our growth forecasts. However, we do not expect significant changes in the competitive landscape of the industry, as several TMS (transcranial magnetic stimulation) companies already have similar approvals.
8 Likes